Abstract

The aim of this study was to prepare carteolol hydrochloride matrix sustained-release pellets, and to compare its performance in vivo with carteolol common tablets. The formula was optimized according to the roundness and the release of pellets with single-factor, and orthogonal test. The carteolol hydrochloride matrix sustained-release pellets were got by extrusion-spheronisaion, while the release rate in vitro was determined by rotate basket method with UV detection. The carteolol hydrochloride sustained release property was studied in New Zealand white rabbits after oral administration. The optimized prescription is composed of carteolol hydrochloride 5.5 g, MCC 6.0 g, SA 26.3 g, EC 21.0 g, CMC-Na 1.2 g. Drug release property in vitro were as follows: the release time is over 12 h, the drug release behaviors follow the first order equation and the process of drug releasing is drug diffusion with frame erosion. The Cmax, Tmax and AUC(0→24) of the pellets were 2.58 ± 0.43 (mg/ml), 4.20 ± 0.87 (h) and 22.19 ± 4.23 (mg/ml h), respectively. The Cmax, Tmax and AUC(0→24) of the tablets were 3.75 ± 0.59 (mg/ml), 1.00 ± 0.72 (h) and 18.70 ± 3.75 (mg/ml h). The carteolol hydrochloride sustained-release pellets have reasonable formulation and simple preparation technology; the pellets acquired perfect sustained-release properties in vitro/in vivo. Key words: Carteolol hydrochloride, sustained-release, pellets, in vitro, in vivo, evaluation

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.